Srx Health Solutions, Inc. · AMEX:SRXH
Srx Health Solutions — Better Choice — Investor Presentation (November 2024)
17 slides from Srx Health Solutions's investor presentation, Nov 5, 2024
Slide 1: Better Choice Company and SRx Health Solutions Investor Presentation
BETTER SR. CHOICE iis COMPANY SOLUTIONS Better Choice Company SRx Health Solutions Investor Presentation October 2024 NYSEAM | BTTR
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS The information in this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contain
Slide 3: The Company
THE COMPANY OUR VISION: PROVIDING BETTER PRODUCTS AND SOLUTIONS FOR PETS, PEOPLE & FAMILIES BETTER CHOICE COMPANY es 2 Pet Health Specialty Care Halo Better Health Rx Specialty Pharmacy Patient Support Programs + Three product lines + Planned expansion + 33 specialty + Adding two PSP's of premium pe
Slide 4: Halo Overview
7-9 HALO OVERVIEW Rooted in Nature Targeting most attractive consumer segments snacks and treats Rapidly Growing International Sales Designed for the pet parent seeking Hal» complete digestive health with prebiotics, probiotics and postbiotics. Adaitionally, sctin it one of the only brands made with
Slide 5: Market Opportunity
MARKET OPPORTUNITY $130B Total Addressable Market? / 6.45% Expected CAGR in Petcare’ $49M HALO 2023 Gross Sales Favorable Industry Dynami ‘The US pet industry continues to grow ata healthy trajectory, with steady growth expected to continue Pet sector enjoys significant investor interest Favorable u
Slide 6: SRx Overview
SRx OVERVIEW & SRx focus is on specialty care in Canada 33 Specialty Pharmacies 40 Specialty Infusion Clinics and Injection Sites 4 Clinical Trial Sites 1 Wholesale & Distribution Facility & Specialty pharmacies dispense specialty drugs which require distribution rights, extensive training and exper
Slide 7: SRx Overview Continued
SRx OVERVIEW CONTINUED Strong Industry Tailwinds The Revenue Model 62 a) of Canadians aged 65+ report having at least 1 chronic disease” of Canadians aged 65+ report having 2 cor more chronic diseases of Canadians indicate they trust pharmacists as their first point of care® more frequent visits to
Slide 8: Summary Income Statement Combined Co
SUMMARY INCOME STATEMENT COMBINED CO 3 months ended 6 months ended Year ended (in thousands of USD) I June 2024* June 2024* December 2023 I Net sales 51,157 94,793 174,493 Cost of sales (38,500) (72,649) (136,315) Gross profit 12,657 22,144 38,178 Operating expenses (15,126) (31,170) (70,277) Other
Slide 9: Pro Forma Capitalization Table
PRO FORMA CAPITALIZATION TABLE Pro Forma Including Shares to be Issued to SRx Health Solutions Shares Outstan 22,911,334 Combined Net Debt (usp)? $20.7 MM Ownership? Non-Afiites 25% wInsiders © Non-Affiliates (1) As of August 27, 2024 and assumes the full exercise of 1,028,000 pre-funded warrants an
Slide 10: Investment Highlights
INVESTMENT HIGHLIGHTS ROBUST GROWTH OPPORTUNITIES IN EACH SEGMENT + Expanding Footprint in APAC + Accelerating Organic Growth + Strategic Acquisition Opportunities + US &EU International Expansion STRONG INDUSTRY TAILWINDS + Growing Prevalence of Chronic Disease in Seniors + ~$5.4% Projected Growth
Slide 11: Thank You!
Thank You! BETTER INVESTOR CONTACT: Cc | 0 | C E janaging Director COMPANY 254
Slide 12: Appendix
APPENDIX
Slide 13: Leadership Team Post Closing
LEADERSHIP TEAM POST CLOSING Michael Young Lead Director Better Choice Company ‘Michael Young is the founding partner of Cottingham Capital. He began investing in Nashville realestate in 2014 after identifying Nashville for both long term ‘growth and a value against other US. real~ festate markets.
Slide 14: Summary Income Statement: SRx Health Solutions
SUMMARY INCOME STATEMENT: SRx HEALTH SOLUTIONS (in thousands of AD) *Thane 2028" one 2024" December 2025" Revenue 58,361 107,297 180,264 Cost of sales 45,482 85,005 145,271 Gross profit 12,879 22,292 34,993 General and administrative 14,450 29,503 50,012 Depreciation and amortization 1,622 3,215 4,4
Slide 15: Summary Income Statement: Better Choice Pre-Acquisition
SUMMARY INCOME STATEMENT: BETTER CHOICE PRE-ACQUISITION (in thousands of USD) Thane 2028" orjane 2088" December 2023 Net sales 8,542 16,445 38,592 Cost of goods sold 5,289 10,578 26,795 Gross profit 3,253 5,867 11,797 “Seling, general and administrative 3,977 9,057 24,444 Net income (loss) 2,654 (17
Slide 16: Reconciliation of Net Loss to EBITDA and Pro Forma Adjusted EBITDA
Reconciliation of Net Loss to EBITDA and Pro Forma Adjusted EBITDA - SRx Health Solutions Pre-Acquisition 3 months ended 6 months ended 12 months ended {in milions of CAD) June 2024* June 2024* December 2023* Net loss @2) (oa) (94) Depreciation 16 32 44 Interest expense 18 4 36 Income tax expense (b
Slide 17: Reconciliation of Net Loss to EBITDA and Adjusted EBITDA
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA Better Choice Pre-Acquisition 3 months ended 6 months ended Year ended (in thousands of USD) June 2024* June 2024* December 2023 Net loss available to common stockholders 2654 76) 22,770) Interest expense, net 180 a2 1353 Income tax expense 3
Better Choice — Investor Presentation (November 2024) on 6ix